ūüéČ Health Canada Provides a No Objection Letter for ATMA‚Äôs N500 Phase II Clinical Trial Application

ATMA Media Releases

ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada

 ATMA Journey Centers Inc. (“ATMA”), Canada’s leading psychedelic-assisted therapy training provider, is pleased to announce it has submitted an N500 3,4-Methylenedioxymethamphetamine (MDMA) phase II Clinical Trial Application (CTA) to Health Canada, which aims …

ATMA Submits N500 MDMA Phase II Clinical Trial Application to Health Canada Read More »

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists

First-of-its-kind clinical trial establishes the Company‚Äôs drug pipeline and strategic plan to supply thousands of therapists VANCOUVER, British Columbia, Feb. 07, 2023 (GLOBE NEWSWIRE) — Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) …

Optimi Health Submits Phase I Clinical Trial Application Combining The Use Of Proprietary Psilocybin and MDMA Drug Candidates In Healthy Therapists Read More »

ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS

In response to¬†Australia’s¬†approval of MDMA and psilocybin use in therapy AUSTRALIA,¬†Feb. 7, 2023¬†/PRNewswire/ —¬†ATMA Journey Centers Inc.¬†(“ATMA”),¬†Canada’s¬†leading psychedelic-assisted therapy training provider, is pleased to offer its psychedelic therapy training programs …

ATMA OFFERS PSYCHEDELIC-ASSISTED THERAPY TRAINING IN AUSTRALIA TO SUPPORT PSYCHIATRISTS AND HEALTHCARE PROFESSIONALS Read More »

ATMA Provides Alberta Health Services (AHS) Healthcare Professionals Group Discount on Psychedelic Therapy Education

CALGARY, ALBERTA, CANADA, January 25, 2023 /EINPresswire.com/ — In response to the new Alberta Regulations on psychedelic assisted therapy,¬†ATMA Journey Centers Inc.¬†(“ATMA”), Canada‚Äôs leading psychedelic-assisted therapy training provider, has announced …

ATMA Provides Alberta Health Services (AHS) Healthcare Professionals Group Discount on Psychedelic Therapy Education Read More »

ATMA and Neuma Centre Partner to Create Access to first of its kind Psilocybin Research Trial in Ontario

KINGSTON, ONTARIO, CANADA, January 5, 2023 /EINPresswire.com/ —¬†ATMA Journey Centers Inc. (“ATMA”), a Canada‚Äôs leading psychedelic-assisted therapy training providers, is pleased to announce their affiliate partnership with¬†Neuma Centre, Kingston‚Äôs first …

ATMA and Neuma Centre Partner to Create Access to first of its kind Psilocybin Research Trial in Ontario Read More »

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

ATMA’s N500 Phase II Clinical Trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB,¬†Sept. 14, 2022¬†/CNW/ –¬†ATMA Journey Centers Inc.¬†(“ATMA”), an¬†Alberta-based company …

Health Canada Provides a No Objection Letter for ATMA‚Äôs N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date Read More »